Craig-Hallum initiated coverage of Eledon Pharmaceuticals (ELDN) with a Buy rating and $12 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELDN:
- Eledon Pharmaceuticals Advances Kidney Transplant Study with Tegoprubart
- Eledon Pharmaceuticals: Promising Advances in Organ Transplant Rejection Prevention with Tegoprubart
- Eledon Pharmaceuticals’ Tegoprubart: Promising Clinical Potential in Kidney Transplantation and Strategic Targeting Advantages
- Sernova enters collaborative research agreement with Eledon Pharmaceuticals
- Eledon Pharmaceuticals assumed with a Buy at H.C. Wainwright